The British Society for Rheumatology Guideline for the Management of Adults With Primary Sjögren's Syndrome

A selection of ocular lubricants available in preserved and non-preserved forms. Most are available both over the counter and on prescription, some are prescription only and others are over the counter only.
^aContain benzalkonium chloride (should be avoided).
^bOver the counter only.
^cPrescription only. MD: multi-dose bottle; SDU: single dose units.

Authors and Disclosures

Elizabeth J. Price¹, Saaeha Rauz^2,3, Anwar R. Tappuni⁴, Nurhan Sutcliffe⁵, Katie L. Hackett^6,7, Francesca Barone^8,9, Guido Granata⁸, Wan-Fai Ng^6,7, Benjamin A. Fisher^8,9, Michele Bombardieri^5,10, Elisa Astorri^5,10, Ben Empson¹¹, Genevieve Larkin¹², Bridget Crampton¹³ and Simon J. Bowman⁹ on behalf of the British Society for Rheumatology Standards, Guideline and Audit Working Group

¹Department of Rheumatology, Great Western Hospital NHS Foundation Trust, Swindon, ²Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, ³Birmingham and Midland Eye Centre, City Hospital NHS Trust, Birmingham, ⁴Institute of Dentistry, Queen Mary University of London, ⁵Department of Rheumatology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Barts Health NHS Trust, London, ⁶Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne, ⁷Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, ⁸Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, ⁹Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, ₁₀Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, ¹¹Community Rheumatology department, Modality partnership, Birmingham, ¹²Ophthalmology, Kings College Hospital, London and ¹³British Sjögren's Syndrome Association, Birmingham, UK

Correspondence to
Elizabeth Price, Great Western Hospital NHS Foundation Trust, Swindon, SN3 6BB, UK. E-mail: Elizabeth.price@gwh.nhs.uk

Disclosure statement
B.A.F. has received honoraria from Novartis and Medimmune. W.-F.N. has provided scientific consultancy for Takeda, MedImmune, UCB, Sanofi, Eli-Lily, AbbVie and have received research support from Resolve Therapeutics. S.B. has consulted for a number of Pharmaceutical Companies in the field of clinical trial design Sjogren's Syndrome (AstraZeneca/Medimmune, BMS, Celgene, Eli Lilly, Glenmark, GSK, MTPharma, Novartis, Ono, Pfizer, Takeda, UCB, xtlbio). F.B. works in a unit that has received funding from GSK and USB. All other authors have declared no conflicts of interest.